白蛋白结合型紫杉醇对TKI治疗失败的晚期肺腺癌患者的疗效

Response of Nab-paclitaxel for Advanced Lung Adenocarcinoma Failed to EGFR-TKI

[目的]探讨白蛋白结合型紫杉醇对既往接受过表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗失败的晚期肺腺癌患者的疗效和安全性。[方法]经过EGFR-TKI治疗后进展的晚期肺腺癌患者41例,采用白蛋白结合型紫杉醇方案130mg/m2(d1,8)单药化疗,每21d为1个周期,2个周期后评价疗效。[结果]41例患者中,部分缓解(PR)13例(31.7%),疾病稳定(SD)21例(51.2%),疾病进展(PD)7例(17.1%),疾病控制率(DCR)82.9%,疾病进展时间(TTP)为4.5个月。主要不良反应是白细胞减少、脱发和腹泻等。[结论]白蛋白结合型紫杉醇对TKI治疗失败后的晚期肺腺癌患者的疗效较好,疾病控制率高,且耐受性良好。

[Purpose] To investigate the response and safety of nab-paclitaxel in advanced lung adenocarcinoma patients failed to previous treatment with EGFR-TKI. [Method] Forty-one cases with advanced lung adenocarcinoma failed to EGFR-TKI were enrolled. All patients were treated with nab-paclitaxel 130mg/m2 on day 1 and 8,and repeated in 21 days. Response was evaluated after two cycles. [Results] Among them, 13 cases （31.7%） achieved partial response（PR）,21 cases （51.2%） stable disease（SD）,and 7 cases （17.1%） progressive disease（PD）. The objective response rate（ORR） was 31.7%,and the disease control rate（DCR）,82.9% ;the median time to progression （TFP）,4.5 months. The common toxicities were leucopenia, alopecia and diarrhea. [Conclusion ] Nab-paclitaxel is effective and safe in treatment of advanced lung adenocarcinoma patients failed to EGFR-TKI, and the toxicities are tolerable.